News|Articles|November 19, 2026

BHV-1530 Shows Responses in FGFR3-Altered Urothelial and Head and Neck Cancers

Fact checked by: Roman Fabbricatore

Partial responses occurred in 6 of 10 evaluable patients with FGFR3-altered tumors treated with BHV-1530, an FGFR3-directed antibody-drug conjugate, in a phase 1 study.

Treatment with BHV-1530, a first-in-class FGFR3-directed antibody-drug conjugate (ADC), produced partial responses (PRs) in 6 of 10 evaluable patients with FGFR3-altered advanced solid tumors, according to phase 1 data from the BHV1530-101 study (NCT06874335) presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) and announced in a news release from the developer, Biohaven.1 Responses occurred in patients with urothelial cancer (UC) whose disease had progressed on enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) and in patients with HPV-positive head and neck squamous cell carcinoma (HNSCC).

What were the efficacy results from the BHV1530-101 study?

As of an October 19, 2026, data cutoff, the efficacy-evaluable population included 10 patients with activating FGFR3 alterations who received BHV-1530 at 3.3 mg/kg or higher.Of these patients, 9 had tumor reductions, and 6 achieved a confirmed or unconfirmed PR per investigator assessment by RECIST v1.1 criteria. Responses occurred in tumors harboring FGFR3 mutations and fusions, and all responders remained on treatment at the cutoff, some for more than 6 months.

Among patients with FGFR3-altered UC, 3 of 5 achieved a PR, including 1 patient who had previously received an FGFR inhibitor. In FGFR3 wild-type UC, 2 patients had tumor reductions, 1 of whom had a PR pending confirmation. All 3 patients with FGFR3-altered, HPV-positive HNSCC achieved a PR.

One patient with HPV-positive metastatic HNSCC harboring an FGFR3 S249C mutation had received 4 prior lines of therapy, including chemoradiation, a platinum doublet, and immunotherapy. This patient had a confirmed PR with a 67% reduction in target lesions at week 6 that deepened to 86% by week 24 and remained on therapy beyond 6 months with no treatment-related adverse effects (TRAEs).

“We also saw deep responses in HPV-positive head and neck cancer, where options after immunotherapy are limited,” said Gerald S. Falchook, MD, director of Sarah Cannon Research Institute at HCA HealthONE, in the press release.1 Falchook presented the findings during a plenary session at ENA 2026 in Barcelona, Spain.

What was the safety profile of BHV-1530?

Across 30 treated patients, investigators reported no dose-limiting toxicities, treatment-related serious adverse effects, or treatment-related deaths. The most common TRAEs were nausea (43%) and fatigue (37%), all of which were grade 1 or 2. Hematologic toxicities were mostly low grade.

No cases of hyperphosphatemia, nail dystrophy, or central serous retinopathy, which are class toxicities of FGFR tyrosine kinase inhibitors (TKIs), were reported, and no interstitial lung disease occurred. Pharmacokinetic analyses showed free payload exposure below 1% of ADC exposure and a half-life of 7 to 14 days, supporting dosing every 3 weeks.

How is the phase 1 BHV1530-101 trial designed?

BHV1530-101 is a first-in-human, open-label, multicenter phase 1 trial evaluating BHV-1530 as monotherapy and in combination with an anti–PD-1 antibody in adults with advanced or metastatic solid tumors.2 Eligible patients must have progressed on, be intolerant of, or have no available standard-of-care therapy. Patients with UC, non–small cell lung cancer, or HNSCC could enroll regardless of FGFR3 status, whereas other tumor types required a documented activating FGFR3 alteration.

In the monotherapy dose escalation, 30 patients received BHV-1530 every 3 weeks at doses ranging from 1.0 to 12.0 mg/kg, and dose escalation is ongoing. Patients had received a median of 2 prior lines of therapy for advanced disease. A combination cohort with cemiplimab-rwlc (Libtayo) is enrolling under a clinical supply agreement with Regeneron.3

What is BHV-1530, and what are the next steps?

BHV-1530 binds FGFR3 on the tumor cell surface, is internalized, and releases Biohaven’s proprietary topoisomerase I (TopoIx) payload, rather than inhibiting FGFR kinase activity. Preclinical studies showed no detectable binding to FGFR1, FGFR2, or FGFR4. According to the company, FGFR3 activating alterations or overexpression occur in about half of metastatic UC cases and in 70% to 80% of non–muscle-invasive bladder cancers, while the only FDA-approved FGFR-targeted therapy for advanced UC is limited to previously treated patients with susceptible FGFR3 alterations.

Biohaven completed a type C meeting with the FDA in the fourth quarter of 2026 and plans to start a pivotal study in FGFR3-altered tumors, beginning with UC, as early as the first half of 2027 to support a potential accelerated approval.

References

  1. Biohaven’s novel FGFR3-directed ADC with proprietary TopoIx payload, BHV-1530, shows clinical activity and confirmed responses in FGFR3-altered urothelial and head and neck cancers, oral presentation at ENA 2026. News release. Biohaven Ltd. November 19, 2026. Accessed November 19, 2026. https://tinyurl.com/48t4usj4
  2. A phase 1 study of BHV-1530 in advanced solid tumors. ClinicalTrials.gov. Updated July 9, 2026. Accessed November 19, 2026. https://tinyurl.com/5eue46bv
  3. Biohaven to present new clinical data at ESMO Congress on BHV-1530, a novel FGFR3-directed ADC with a proprietary topoisomerase I (TopoIx) payload. News release. Biohaven Ltd. July 20, 2026. Accessed November 19, 2026. https://tinyurl.com/38p8hzpp

Related to this article